"Escape" Phenomenon of the Antihypertensive Therapy Efficacy

Active, not recruiting

• Conditions: Arterial Hypertension
• Interventions: Device: Ambulatory blood pressure measurement device; Device: Sphygmocor; Device: VaSera-VS; Device: Somnocheck

• Registration Number: NCT05436730
• Lead Sponsor: Federal State Budgetary Institution NATIONAL MEDICAL RESEARCH CENTRE OF CARDIOLOGY NAMED AFTER ACADE

Brief Summary

A little attention is paid to the AHT efficacy escaping problem, which can be explained by the AHT correction simplicity and rapid achievement of the target BP level. Nevertheless, modern statistic data on the effective AH treatment described above let us assume that AHT correction is either totally absent or is untimely in case of the "escape" phenomenon development. This could be one of the main reasons for the high prevalence of ineffective AH treatment. The aim of this study is to determine AHT efficacy "escape" phenomenon timeline and its predictors in hypertensive patients.

Detailed Description

Not available

Study Timeline

• Study Start: 2015-09-29
• Primary Completion: 2016-12-30
• Status Verified: 2022-06
• Study First Submitted: 2022-06-22
• Study First Submitted QC: 2022-06-28
• Last Update Submitted: 2022-06-28
• Study First Posted: 2022-06-29
• Last Update Posted: 2022-06-29
• Study Completion: 2025-12-30

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 165

Inclusion Criteria

• Arterial hypertension (AH) grade 1-3, stage I-II
• High compliance during the follow-up period (≥ 85%)
• Initially achieved target office BP levels while taking 2-3-component AHT

Exclusion Criteria

• Secondary AH
• Resistant AH,
• AH III stage,
• PAP- therapy,
• type 2 diabetes mellitus,
• pregnancy
• history of low adherence to treatment

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
"Escape" Phenomenon of the Antihypertensive Therapy Efficacy	Ambulatory blood pressure measurement device	Men and women aged 18-90 years with arterial hypertension grade 1-3, stage I-II and initially achieved target BP levels while taking 2-3-component AHT.
"Escape" Phenomenon of the Antihypertensive Therapy Efficacy	VaSera-VS	Men and women aged 18-90 years with arterial hypertension grade 1-3, stage I-II and initially achieved target BP levels while taking 2-3-component AHT.
"Escape" Phenomenon of the Antihypertensive Therapy Efficacy	Sphygmocor	Men and women aged 18-90 years with arterial hypertension grade 1-3, stage I-II and initially achieved target BP levels while taking 2-3-component AHT.
"Escape" Phenomenon of the Antihypertensive Therapy Efficacy	Somnocheck	Men and women aged 18-90 years with arterial hypertension grade 1-3, stage I-II and initially achieved target BP levels while taking 2-3-component AHT.

Primary Outcome Measures

Name	Time	Method
Assessment of BP increasing higher the target level when taking the same therapy	1-6 months	Assessment of attenuation of efficacy of previously adequate antihypertensive therapy by using different BP measurement methods

Secondary Outcome Measures

Name	Time	Method
Disease course: assessment of major CVE and death occurrence	10 years	Assessment of the disease course depending on the characteristics of 3-6th months of observation

Trial Locations

Locations (1)

Oksana Mikhailova; 🇷🇺 Moscow, Russian Federation